ArriVent BioPharma, Inc.
AVBP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$21.00
KIRA · Stoqly’s AI analyst, in plain words
- ArriVent BioPharma, Inc. lost $166M in fiscal 2025.
Market cap
$1,000M
P/E
—
Revenue
—
Net income
−$166M
Free cash flow
—
Operating margin
—
ArriVent BioPharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$166M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ArriVent BioPharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- ArriVent BioPharma, Inc.
- CIK
- 0001868279
ArriVent BioPharma, Inc. · AVBP
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$69.3M | −$80.5M | −$166M |
| Diluted EPS | −$32.38 | −$2.56 | −$4.32 |
| Cash | |||
| Cash from operations | −$55.8M | −$70.2M | −$161M |
| Share count change | — | 1,369.8% | 22.2% |
| Debt and strength | |||
| Cash and short-term investments | $150M | $219M | $313M |
| Shareholders' equity | −$153M | $258M | $307M |
| Current ratio | 13.8x | 13.1x | 12.8x |
| Returns and quality | |||
| Return on equity | — | −154.1% | −58.9% |
| Return on tangible equity | — | −31.2% | −54.1% |
| Altman Z'' | −13.9 | 15.5 | 10.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$13.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ArriVent BioPharma, Inc. · AVBP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.00 a share, the company is worth $1,000M.
Source: SEC EDGAR XBRL filings (CIK 0001868279). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.